Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

NCT00118261 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: erlotinib hydrochloride
DRUG: fluorouracil
DRUG: leucovorin calcium
DRUG: oxaliplatin

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]